RecruitingPhase 1NCT04855656

Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors

Phase 1/1b Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors

Sponsor

Debiopharm International SA

Enrollment

464 participants

Start Date

Apr 30, 2021

Study Type

INTERVENTIONAL

Conditions

Advanced Solid Tumor

Summary

The primary purpose of this study is to assess the safety and tolerability of lunresertib alone and in combination with RP-3500 or in combination with Debio 0123 in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) and assess preliminary anti-tumor activity.

Eligibility

Min Age: 12 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Debio0123, a drug called Lunresertib, and others for people with advanced solid tumor. The study is currently recruiting participants at 22 locations. People eligible for this study include aged 12 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGLunresertib

Oral PKMYT1 Inhibitor

DRUGRP-3500

Oral ATR Inhibitor

DRUGDebio0123

Oral WEE1 Inhibitor

Locations(22)

# 1019, UCLA, Westwood Cancer Center

Los Angeles, California, United States

#1025, University of California San Francisco

San Francisco, California, United States

#1012, Yale

New Haven, Connecticut, United States

#1017, Mayo Clinic

Jacksonville, Florida, United States

#1002, Dana Farber Cancer Institute

Boston, Massachusetts, United States

#1023, START Midwest

Grand Rapids, Michigan, United States

#1016, Mayo Clinic

Rochester, Minnesota, United States

#1011, Washington University

St Louis, Missouri, United States

#1032, Northwell Health Cancer Institute

New Hyde Park, New York, United States

#1008, Columbia University

New York, New York, United States

#1004, Memorial Sloan Kettering Cancer Institute

New York, New York, United States

#1010, University of Pennsylvania

Philadelphia, Pennsylvania, United States

#1007, Rhode Island Hospital

Providence, Rhode Island, United States

#1030, Women & Infants Hospital of Rhode Island

Providence, Rhode Island, United States

#1001, The University of Texas M.D. Anderson Cancer Center

Houston, Texas, United States

#1013, The University of Utah

Salt Lake City, Utah, United States

#1027, University of Virginia

Charlottesville, Virginia, United States

#2002, The Hospital for Sick Children

Toronto, Ontario, Canada

#2001, Princess Margaret Cancer Centre

Toronto, Ontario, Canada

#2003, The Research Institute of the McGill University Health Centre

Montreal, Quebec, Canada

#4001, Rigshospitalet - Blegdamsvej

Copenhagen, Denmark

#3003, Sarah Cannon Research Institute

London, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04855656

Related Trials

Metformin Combined With Chemotherapy and/or Immunotherapy in Solid Malignancies

NCT0709829910 locations

A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors

NCT057658518 locations

A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors

NCT0741483616 locations

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

NCT0654594218 locations

An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors

NCT0722226729 locations